ADC Conjugation Kit (Exatecan, 1mg, for human IgG4&mouse IgG)

Materials Provided

Product Overview

Antibody-drug conjugates (ADCs) deliver potent cytotoxic drugs specifically to tumor cells, thereby enhancing antitumor efficacy and reducing the adverse systemic effects of the cytotoxic drugs. This kit is developed based on interchain cysteine conjugation technology: the interchain disulfide bonds of antibodies can be reduced to generate endogenous interchain cysteine residues, and payload drugs with maleimide functional groups can specifically conjugate to these cysteine residues to form structurally stable ADCs. Relying on this classic conjugation strategy, the kit enables a rapid and controllable ADC preparation process that takes only 3 hours in total, achieving a conjugation efficiency greater than 90% and yielding a product with over 90% purity. The resulting ADC conjugates exhibit significant cytotoxic activity, providing a reliable experimental tool for ADC drug screening and mechanism research.

Application

The ADC Conjugation Kit is designed for conjugation of human IgG4 or mouse lgG with the cytotoxic payload Exatecan through thiol and maleimide reaction chemistry. The ADC products can be used in cellular or animal experiments for the screening of suitable ADC candidates.

It is for research use only.

Features

1. Short Conjugation Time: Generates antibody-drug conjugates (ADCs) within 3 hours.
2. High Conjugation Efficiency & Recovery: Conjugation efficiency > 90%, antibody recovery rate > 80%.
3. No Need for High-Concentration Antibodies: Reaction feasible with only 2 mg/mL of antibodies.
4. Simple Purification: Purification completed in 15 minutes using spin desalting columns.

Storage

BoxA: This product remains stable when stored at -20℃ for 24 months.

BoxB: This product remains stable when stored at 2-8℃ for 24 months.

Please ensure use prior to the expiration date indicated on the packaging.

ACRO Quality Management System

1. QMS(ISO, GMP)
2. Quality Advantages
3. Quality Control Process